Beyond Dupixent®
We’re building on the success of Dupixent® in atopic dermatitis and asthma, developing new solutions for people with debilitating immuno-dermatological, rheumatic, respiratory, and gastrointestinal diseases.
Scaling up innovation
We partner with companies that bring cutting-edge technologies and transformative assets in immuno-inflammation. We bring expertise in biological pathways, research-enabling technologies, proven precision-medicine approaches to clinical development, and robust commercial organization.
Partnering success stories
Regeneron
This global collaboration produced Dupixent®, a novel biologic approved for atopic dermatitis, severe asthma, and eosinophilic esophagitis, and in development for a range of additional potential indications.
Kymera
In partnership with Kymera, we develop and commercialize first-in-class protein degrader therapies that target IRAK4 in patients with immuno-inflammatory diseases.
ImmuNext
We’re working on a CD40L monoclonal antibody (INX-021) initially developed by ImmuNext, as a treatment for autoimmune diseases including lupus and multiple sclerosis.
Your partnering leads in Immunology
For more information, contact our Business development team
Mark Dowling
Head of External Innovation, Immunology
Ulrich Wendt
Global Head of Business Development, Immunology